Results 11 to 20 of about 19,188,680 (306)

Second-Line Treatment for Pancreatic Cancer [PDF]

JOP : Journal of the pancreas, 2014
Although standard of care for treatment of pancreatic cancer is established in the first line setting, there is limited data to support standard for second line chemotherapy for advanced pancreatic cancer. This is starting to change, as new studies have shown positive effect on overall survival in the second line setting.
Nancy, Kaddis, Muhammad Wasif, Saif
openaire   +3 more sources

Second-line Treatment for Faecal Incontinence

Scandinavian Journal of Gastroenterology, 2002
In the treatment of faecal incontinence, more than 30% of patients experience continuation of their problem. We discuss new therapeutic procedures for dealing with faecal incontinence.Discussion of authors' own work in relation to the literature.First-line care includes diets, constipating drugs, biofeedback therapy, anal repair and operations for ...
Baeten, C.G.M.I., Uludag, Ö
openaire   +4 more sources

The association between effectiveness of first-line treatment and second-line treatment in gastro-oesophageal cancer [PDF]

European Journal of Cancer, 2021
Population-based predictive factors for the effectiveness of second-line palliative systemic therapy in gastro-oesophageal cancer are not available. This study investigates the predictive value of effectiveness of first-line treatment for second-line treatment outcomes in gastro-oesophageal cancer in a real-world setting.Patients with metastatic gastro-
Merel J.M. van Velzen, Marieke Pape, Willemieke P.M. Dijksterhuis, Marije Slingerland, Theo van Voorthuizen, Laurens V. Beerepoot, Geert-Jan Creemers, Sarah Derks, Nadia H. Mohammad, Rob H.A. Verhoeven, Hanneke W.M. van Laarhoven   +10 more
openaire   +5 more sources

Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea

ClinicoEconomics and Outcomes Research, 2016
Gabriel Tremblay,1 Unnati Majethia,2 Janis L Breeze,3 Ilias Kontoudis,4 Jeongae Park5 1Geneconomics Inc., Lévis, Quebec, Canada; 2Global Value and Access, Eisai Inc., Woodcliff Lake, NJ, 3Tufts Clinical and Translational Science Institute, Tufts ...
Tremblay G, Majethia U, Breeze JL, Kontoudis I, Park J   +4 more
doaj   +1 more source

Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy

ClinicoEconomics and Outcomes Research, 2012
Bjoern Schwander,1 Simona Ravera,2 Giovanni Giuliani,2 Mark Nuijten,3 Stefan Walzer11Assessment-in-Medicine (AiM) GmbH, Loerrach, Germany; 2Roche SpA, Monza, Italy; 3Ars Accessus Medica, Amsterdam (Jisp), NetherlandsBackground: Lung cancer is the leading
Schwander B, Ravera S, Giuliani G, Nuijten M, Walzer S   +4 more
doaj   +1 more source

Sirolimus as a Second-Line Treatment for Graves’ Orbitopathy

Journal of Endocrinological Investigation, 2022
Background: A beneficial effect of sirolimus in Graves’ orbitopathy (GO) was reported, suggesting its possible use in clinical practice.Methods Observational, single-centre, no-profit, clinical study to investigate the efficacy of sirolimus as a second-line treatment for moderate-to-severe, active GO compared with methylprednisolone. &
Lanzolla, G, Maglionico, M N, Comi, S, Menconi, F, Piaggi, P, Posarelli, C, Figus, M, Marcocci, C, Marino', Michele   +8 more
openaire   +4 more sources

Second-Line Treatment of Ovarian Cancer [PDF]

The Oncologist, 2000
Abstract Patients with epithelial ovarian cancer are often diagnosed with advanced-stage disease. Although clinical complete remissions are obtained in the majority of patients through a combination of cytoreductive surgery and chemotherapy, relapse is common.
M, Markman, M A, Bookman
openaire   +2 more sources

Second-line treatment for renal cell cancer [PDF]

British Journal of Cancer, 2012
In metastatic renal cell carcinoma (mRCC), the transition to the targeted therapy era has made available a variety of effective new agents, including vascular endothelial growth factor tyrosine kinase receptor (VEGF-TKR) inhibitors, such as sunitinib, pazopanib, sorafenib; anti-VEGF monoclonal antibody bevacizumab; and mTOR (mammalian target of ...
Di Lorenzo, G, DE PLACIDO, SABINO, Buonerba, C.   +2 more
openaire   +3 more sources

Immunological failure of first-line and switch to second-line antiretroviral therapy among HIV-infected persons in Tanzania: analysis of routinely collected national data. [PDF]

, 2015
OBJECTIVES: Rates of first-line treatment failure and switches to second-line therapy are key indicators for national HIV programmes. We assessed immunological treatment failure defined by WHO criteria in the Tanzanian national HIV programme. METHODS: We
Ramadhani, Angela, Vanobberghen, Fiona M, Mmbando, Donan, Wringe, Alison, Todd, Jim, Zaba, Basia, Kilama, Bonita   +6 more
core   +1 more source

Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies. [PDF]

, 2012
Article approval pendingTenofovir (TDF) is increasingly used in second-line antiretroviral treatment (ART) in sub-Saharan Africa. We compared outcomes of second-line ART containing and not containing TDF in cohort studies from Zambia and the Republic of ...
Brennan, Alana, Olivia Keiser, Cleophas Chimbetete, Lloyd Mulenga, Giddy, Janet, Egger, Matthias, Hans Prozesky, Janet Giddy, Wandeler, Gilles, Alana Brennan, Christopher J. Hoffmann, Robin Wood, Thom Chaweza, Chaweza, Thom, Daniela Garone, Gilles Wandeler, Matthias Egger, Keiser, Olivia, Mulenga, Lloyd, Hoffmann, Christopher J, Chimbetete, Cleophas, Prozesky, Hans, Boulle, Andrew, Garone, Daniela, IeDEA Southern Africa Collaboration,, Andrew Boulle, Wood, Robin, Egger M, Wandeler G, Giddy J, Hoffmann CJ, Chimbetete C, Garone D, Chaweza T, Mulenga L, Boulle A, Brennan A, Prozesky H, Wood R, Keiser O   +39 more
core   +3 more sources